50% Off! Beat the market in 2025 with InvestingProCLAIM SALE

Long COVID at 12 months persists at 18 months, study shows

Published 10/16/2022, 12:04 PM
Updated 10/16/2022, 12:11 PM
© Reuters. FILE PHOTO: A person waits to get a COVID-19 test during the coronavirus disease (COVID-19) pandemic in the Manhattan borough of New York City, New York, U.S., January 12, 2022.  REUTERS/Carlo Allegri

(This Oct. 13 story has been corrected to changes last percentage in paragraph 4 from 39% to 38%.)

By Nancy Lapid

(Reuters) - Most patients with COVID-19 who have lingering symptoms at 12 months are likely to still have symptoms at 18 months, new data suggest.

The findings are drawn from a large study of 33,281 people in Scotland who tested positive for the coronavirus. Most of the results are in line with those from earlier, smaller studies.

Among a subset of 197 survivors of symptomatic SARS-CoV-2 infections who completed surveys at 12 months and 18 months, most reported lingering symptoms at both time points, researchers reported in Nature Communications.

Rates of no recovery at 12 months were 11% with 51% partial recovery and 39% complete recovery. Rates at 18 months were 11% no recovery, 51% partial and 38% complete.

Asymptomatic infections were not associated with long COVID. But among the 31,486 people with symptomatic infections, nearly half reported incomplete recovery at six to 18 months.

A total of 3,744 participants with symptomatic infections completed questionnaires twice over the following year. At six months, 8% reported no recovery, 47% reported partial recovery, and 45% reported complete recovery. Those rates had barely changed at 12 months, with 8% reporting no recovery, 46% partial recovery and 46% complete recovery.

One in 20 patients with a symptomatic infection reported no recovery at the most recent follow-up, researchers said.

"Our study is important because it adds to our understanding of long COVID in the general population, not just in those people who need to be admitted to hospital with COVID-19," study leader Jill Pell of the University of Glasgow said in a statement.

Long COVID was more likely in patients who had been hospitalized and in those who were older, female, socioeconomically disadvantaged, and with pre-existing health conditions. The most common lingering symptoms included breathlessness, chest pain, palpitations, and confusion and "brain fog."

© Reuters. FILE PHOTO: A person waits to get a COVID-19 test during the coronavirus disease (COVID-19) pandemic in the Manhattan borough of New York City, New York, U.S., January 12, 2022.  REUTERS/Carlo Allegri

Vaccination before infection appeared to protect against some long-term symptoms, the researchers also found.

The researchers also surveyed nearly 63,000 individuals with only negative COVID tests, to distinguish between health problems that are due to COVID-19 and health problems that would be expected in the general population.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.